ArticleMethods in molecular biology (Clifton, N.J.)2012
Yeast display of engineered antibody domains.
Article in Methods in molecular biology (Clifton, N.J.), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 15 citations in OpenAlex.
- Rational engineering and yeast surface display of Epinecidin-1 peptides reveal antimicrobial activity and selective anticancer effects.Molecular biology reports · 2026Article
- Development of broadly neutralizing antibodies against Omicron variants from existing neutralizing antibodies in clinical trials.Virology journal · 2025Article
- Ultra-High-Throughput Screening of Cystine-Rich Peptide Libraries Via Yeast Surface Display.Methods in molecular biology (Clifton, N.J.) · 2025Article
- A dual-specific IGF-I/II human engineered antibody domain inhibits IGF signaling in breast cancer cells.International journal of biological sciences · 2018Article
- Engineered antibody CH2 domains binding to nucleolin: Isolation, characterization and improvement of aggregation.Biochemical and biophysical research communications · 2017Article
- N-terminal residues of an HIV-1 gp41 membrane-proximal external region antigen influence broadly neutralizing 2F5-like antibodies.Virologica Sinica · 2015Article
- Affinity maturation of T-cell receptor-like antibodies for Wilms tumor 1 peptide greatly enhances therapeutic potential.Leukemia · 2015Article
- Alteration of Electrostatic Surface Potential Enhances Affinity and Tumor Killing Properties of Anti-ganglioside GD2 Monoclonal Antibody hu3F8.The Journal of biological chemistry · 2015Article
- Applications of Yeast Surface Display for Protein Engineering.Methods in molecular biology (Clifton, N.J.) · 2015Review
- Discovery of novel candidate therapeutics and diagnostics based on engineered human antibody domains.Current drug discovery technologies · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Yeast display is an efficient technology for selection of antibodies and other proteins with high affinity and thermal stability. Here, we describe a method for affinity maturation of engineered antibody domains (eAds) using yeast display. EAd yeast libraries of relatively large size (∼10⁹) were generated and subjected to alternating rounds of magnetic-activated cell sorting (MACS), fluorescent-activated cell sorting (FACS), and random mutagenesis. The highest affinity clones from the final round of maturation were identified and analyzed. We discuss extensively each key step, and provide detailed protocols and helpful notes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.